Literature DB >> 17220354

RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia.

Zhenglin Gu1, Qian Jiang, Zhen Yan.   

Abstract

Regulator of G protein signaling 4 (RGS4) has recently been identified as one of the genes linked to the susceptibility of schizophrenia. However, the functional roles of RGS4 and how it may be involved in the pathophysiology of schizophrenia remain largely unknown. In this study, we investigated the possible impact of RGS4 on the function of serotonin and dopamine receptors, two main targets for schizophrenia treatment. Activation of serotonin 5-HT(1A) receptors or dopamine D(4) receptors down-regulates the function of NMDA receptor (NMDAR) channel, a key player controlling cognition and emotion, in pyramidal neurons of prefrontal cortex (PFC). Blocking RGS4 function significantly potentiated the 5-HT(1A) regulation of NMDAR current; conversely, overexpression of RGS4 attenuated the 5-HT(1A) effect. In contrast, the D(4) regulation of NMDAR current was not altered by RGS4 manipulation. Moreover, the 5-HT(1A) regulation of NMDA receptors was significantly enhanced in a subset of PFC pyramidal neurons from rats treated with subchronic phencyclidine, an animal model of schizophrenia, which was found to be associated with specifically decreased RGS4 expression in these cells. Thus, our study has revealed an important coupling of RGS4 to serotonin signaling in cortical neurons and provided a molecular and cellular mechanism underlying the potential involvement of RGS4 in the pathophysiology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220354     DOI: 10.1124/mol.106.032490

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  25 in total

1.  Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex.

Authors:  Eunice Y Yuen; Jing Wei; Wenhua Liu; Ping Zhong; Xiangning Li; Zhen Yan
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

2.  Cellular noise suppression by the regulator of G protein signaling Sst2.

Authors:  Gauri Dixit; Joshua B Kelley; John R Houser; Timothy C Elston; Henrik G Dohlman
Journal:  Mol Cell       Date:  2014-06-19       Impact factor: 17.970

3.  Regulators of G protein signaling (RGS) proteins as drug targets: modulating G-protein-coupled receptor (GPCR) signal transduction.

Authors:  David L Roman; John R Traynor
Journal:  J Med Chem       Date:  2011-09-29       Impact factor: 7.446

4.  Chronic intermittent ethanol exposure selectively alters the expression of Gα subunit isoforms and RGS subtypes in rat prefrontal cortex.

Authors:  D J Luessen; H Sun; M M McGinnis; B A McCool; R Chen
Journal:  Brain Res       Date:  2017-07-21       Impact factor: 3.252

5.  Effect of tandospirone, a serotonin-1A receptor partial agonist, on information processing and locomotion in dizocilpine-treated rats.

Authors:  Vera Bubenikova-Valesova; Jan Svoboda; Jiri Horacek; Tomiki Sumiyoshi
Journal:  Psychopharmacology (Berl)       Date:  2010-07-31       Impact factor: 4.530

6.  Association of polymorphisms in RGS4 and expression of RGS transcripts in the brains of human alcoholics.

Authors:  Ada M-C Ho; Rachel K MacKay; Peter R Dodd; Joanne M Lewohl
Journal:  Brain Res       Date:  2010-04-27       Impact factor: 3.252

7.  The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors.

Authors:  Isaac J Dripps; Qin Wang; Richard R Neubig; Kenner C Rice; John R Traynor; Emily M Jutkiewicz
Journal:  Psychopharmacology (Berl)       Date:  2016-09-13       Impact factor: 4.530

8.  Gene expression profiling of rat cerebral cortex development using cDNA microarrays.

Authors:  Ki-Hwan Lee; Dong-Hyun Yu; Yong-Sung Lee
Journal:  Neurochem Res       Date:  2008-11-06       Impact factor: 3.996

Review 9.  Roles for Regulator of G Protein Signaling Proteins in Synaptic Signaling and Plasticity.

Authors:  Kyle J Gerber; Katherine E Squires; John R Hepler
Journal:  Mol Pharmacol       Date:  2015-12-11       Impact factor: 4.436

Review 10.  Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Authors:  Yael Chertkow; Orly Weinreb; Moussa B H Youdim; Henry Silver
Journal:  J Neural Transm (Vienna)       Date:  2009-07-04       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.